Tiziana Life Sciences PLC (NASDAQ:TLSA) saw some unusual options trading on Wednesday. Stock traders acquired 2,564 call options on the company. This is an increase of approximately 2,881% compared to the typical volume of 86 call options.
A number of research firms have recently weighed in on TLSA. HC Wainwright reissued a “buy” rating and issued a $11.00 target price (down previously from $25.00) on shares of Tiziana Life Sciences in a research note on Monday, September 21st. Zacks Investment Research lowered Tiziana Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. B. Riley initiated coverage on Tiziana Life Sciences in a research note on Tuesday, December 22nd. They issued a “buy” rating and a $8.00 target price for the company. Finally, BidaskClub raised Tiziana Life Sciences from a “hold” rating to a “buy” rating in a research report on Friday, October 9th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $7.58.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ausdal Financial Partners Inc. bought a new position in Tiziana Life Sciences during the 3rd quarter valued at approximately $51,000. Wedbush Securities Inc. bought a new position in shares of Tiziana Life Sciences in the 3rd quarter worth approximately $57,000. Orion Portfolio Solutions LLC bought a new position in shares of Tiziana Life Sciences in the 3rd quarter worth approximately $59,000. State Street Corp bought a new position in shares of Tiziana Life Sciences in the 3rd quarter worth approximately $645,000. Finally, Morgan Stanley raised its position in shares of Tiziana Life Sciences by 2,700.7% in the 3rd quarter. Morgan Stanley now owns 350,005 shares of the company’s stock worth $1,165,000 after acquiring an additional 337,508 shares in the last quarter. 2.21% of the stock is owned by institutional investors and hedge funds.
About Tiziana Life Sciences
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
Further Reading: Most Active Stocks
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.